Title Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in combination with FOLFOX chemotherapy as a first-line treatment for gastric cancer patients with peritoneal metastases: single-arm phase II study /
Authors Lukšta, Martynas ; Baušys, Augustinas ; Bičkaitė, Klaudija ; Račkauskas, Rokas ; Paškonis, Marius ; Lukšaitė-Lukštė, Raminta ; Ranceva, Anastasija ; Stulpinas, Rokas ; Brasiūnienė, Birutė ; Baltruškevičienė, Edita ; Lachej, Nadežda ; Sabaliauskaitė, Rasa ; Baušys, Rimantas ; Tulytė, Skaistė ; Strupas, Kęstutis
DOI 10.1186/s12885-023-11549-z
Full Text Download
Is Part of BMC cancer.. London : BioMed Central Ltd. 2023, vol. 23, iss. 1, art. no. 1032, p. [1-9].. eISSN 1471-2407
Keywords [eng] gastric cancer ; peritoneal metastases ; PIPAC
Abstract [eng] Background: Gastric cancer (GC) remains among the most common and most lethal cancers worldwide. Peritoneum is the most common site for distant dissemination. Standard treatment for GC peritoneal metastases (PM) is a systemic therapy, but treatment outcomes remain very poor, with median overall survival ranging between 3-9 months. Thus, novel treatment methods are necessary. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is the most novel technique for intraperitoneal chemotherapy. Some preliminary data suggest PIPAC can achieve improved long-term outcomes in patients with GC PM, especially when used in combination with systemic chemotherapy. However, there is a lack of data from well-design prospective studies that would confirm the efficacy of PIPAC and systemic therapy combination for first-line treatment. Methods: This study is an investigator-initiated single-arm, phase II trial to investigate the efficacy of PIPAC combined with systemic FOLFOX (5-fluorouracil, oxaliplatin, leucovorin) as a first-line treatment for GC PM. The study is conducted in 2 specialized GC treatment centers in Lithuania. It enrolls GC patients with histologically confirmed PM without prior treatment. The treatment protocol consists of PIPAC with cisplatin (10.5 mg/m2 body surface in 150 mL NaCl 0.9%) and doxorubicin (2.1 mg/m2 in 50 mL NaCl 0.9%) followed by 2 cycles of FOLFOX every 6–7 weeks. In total 3 PIPACs and 6 cycles of FOLFOX will be utilized. The primary outcome of the study is the objective response rate (ORR) according to RECIST v. 1.1 criteria (Eisenhauer et al., Eur J Cancer 45:228–47) in a CT scan performed 7 days after the 4th cycle of FOLFOX. Secondary outcomes include ORR after all experimental treatment, PIPAC characteristics, postoperative morbidity, histological and biochemical response, ascites volume, quality of life, overall survival, and toxicity. Discussion: This study aims to assess PIPAC and FOLFOX combination efficacy for previously untreated GC patients with PM. Trial registration: NCT05644249. Registered on December 9, 2022.
Published London : BioMed Central Ltd
Type Journal article
Language English
Publication date 2023
CC license CC license description